Xalud Therapeutics is a clinical-stage biotechnology company based in New York, NY, that is dedicated to developing a non-viral plasmid DNA-delivered gene therapy platform to treat chronic inflammatory diseases by restoring balance in the immune system.
Their lead candidate, XT-150, is a locally injectable gene therapy that expresses a modified version of interleukin-10 (IL-10v), a potent cytokine that regulates multiple inflammatory pathways. Xalud aims to transform the treatment of chronic inflammatory diseases by addressing the underlying cause of the disease and improving the lives of patients burdened by these conditions.
Generated from the website